Subcutaneous versus intravenous nivolumab for renal cell carcinoma
Laurence Albigès, María T. Bourlon, Matías Chacón, Hernán Cutuli, Yamil Alonso Lopez Chuken, Bogdan Żurawski, José Maurício Mota, Ignacio Magrí, Mauricio Burotto, Murilo Luz, Juliana De Menezes, Eduardo Patricio Yanez Ruiz, Simon Fu, Martin Eduardo Richardet, Begoña P. Valderrama, Marco Maruzzo, Sergio Bracarda, Mary Alice B. Breckenridge, Heather Vezina, Darshana Rathod, Zhuoxin Yu, Yingchao Zhao, Matthew Dixon, Deepak Perumal, Shaji George
Topics & Concepts
MedicineNivolumabRenal cell carcinomaOncologyCarcinomaInternal medicineUrologyImmunotherapyCancerCancer Immunotherapy and BiomarkersRenal cell carcinoma treatmentInflammatory Biomarkers in Disease Prognosis